CD8A and neoplasm: 1. ATOR-1015 activates T cells and reduces Tregs in vitro.2. In various preclinical models, ATOR-1015 reduces tumor growth and improves survival, including in bladder, colon, and pancreas cancer models.3. ATOR-1015 generates long-term tumor-specific immunological memory and enhances response to PD-1 inhibition.4. ATOR-1015 targets the tumor area, where it boosts the number and activation of CD8+ T-cells and decreases Tregs.